Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation

The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchial Asthma Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Aichi, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma

Exclusion criteria

Treatment and study plan

Primary outcomes

Incidence of Adverse Events

Time frame: Range of one year

Secondary outcomes

The level of asthma control under long-term use

Time frame: At the end of 24 weeks
The level of asthma control under long-term use

Time frame: At the end of one year

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation for Long-term Use

Acronym: ENSURE

Important dates

Study start: 2010
Primary completion: 2013
Study completion: 2013
First posted: Nov 2, 2010
Registry last updated: May 29, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed